Physician profile
John E Reardon
NPI 1679786354
$6,801.26
in general payments reported to CMS, 2019-2025
56 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $145 · 2021: $445 · 2022: $723 · 2023: $1,213 · 2024: $1,922 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854 · Education: $23.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.55 |
| Education | $23.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $676.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $581.03 | 2019-2025 | |
| Celgene Corporation | $463.00 | 2021-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $446.45 | 2021-2025 | Erleada, Balversa, Akeega |
| Exelixis INC. | $351.69 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $330.90 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $298.90 | 2023-2025 | Libtayo, Lynozyfic |
| Astrazeneca Pharmaceuticals Lp | $248.09 | 2020-2025 | Calquence, Lynparza, Enhertu |
| Incyte Corporation | $228.51 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Beigene USA, INC. | $206.50 | 2021-2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $171.81 | 2019-2025 | Tecentriq, Polivy |
| Abbvie INC. | $171.48 | 2022-2025 | |
| Astellas Pharma US INC | $171.12 | 2019-2025 | Padcev, Xospata, Vyloy |
| Pharmaessentia USA Corporation | $154.48 | 2023-2025 | Besremi |
| Daiichi Sankyo INC. | $148.11 | 2022-2025 | Enhertu, Injectafer |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $145.55 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Genzyme Corporation | $140.25 | 2023-2025 | |
| Genmab U.S., INC. | $132.51 | 2023-2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Eisai INC. | $128.95 | 2021-2024 | |
| Seagen INC. | $127.52 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Glaxosmithkline, LLC. | $118.53 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Array Biopharma INC | $114.90 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $85.53 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $85.16 | 2022-2023 | Imbruvica |
| Amgen INC. | $76.90 | 2019-2022 | |
| Stemline Therapeutics INC. | $72.02 | 2024-2025 | Orserdu |
| Gilead Sciences, INC. | $63.05 | 2021-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $59.78 | 2023-2025 | Monoferric |
| Emd Serono, INC. | $55.24 | 2023-2024 | Bavencio |
| Springworks Therapeutics, INC. | $51.37 | 2024-2025 | Ogsiveo |
| Karyopharm Therapeutics INC. | $44.57 | 2021-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.78 | 2025 | |
| Aveo Pharmaceuticals, INC. | $38.59 | 2024-2025 | |
| Beone Medicines USA, INC. | $33.15 | 2025 | Tevimbra |
| Servier Pharmaceuticals LLC | $30.82 | 2025 | |
| Mirati Therapeutics, INC. | $27.74 | 2023 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $27.60 | 2021-2022 | |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Kite Pharma, INC. | $26.58 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $24.89 | 2024 | Ultomiris |
| Epizyme, INC. | $23.54 | 2021 | |
| Dendreon Pharmaceuticals LLC | $23.41 | 2025 | Provenge |
| Ipsen Biopharmaceuticals, INC | $21.35 | 2022 | |
| Recordati_rare_diseases_inc. | $17.51 | 2023 | Sylvant |
| Adc Therapeutics America, INC. | $16.86 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.19 | 2022 | |
| Novocure INC. | $15.89 | 2025 | Optune Lua (Novottf-200t) |
| Dova Pharmaceuticals | $15.80 | 2020 | |
| Clovis Oncology, INC. | $15.67 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.73 | 2025 | Vivimusta, Danziten |
| Tesaro, INC. | $13.66 | 2019 | |
| Apellis Pharmaceuticals, INC. | $13.58 | 2024 | Empaveli |
| Lilly USA, LLC | $13.38 | 2024 | Retevmo, Jaypirca, Verzenio |
| Morphosys, US INC. | $11.54 | 2021 | |
| Puma Biotechnology, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reardon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.